|
1
|
Albain KS, Swann RS, Rusch VW, Turrisi AT
III, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara
DR, et al: Radiotherapy plus chemotherapy with or without surgical
resection for stage III non-small-cell lung cancer: A phase III
randomised controlled trial. Lancet. 374:379–386. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Eberhardt WE, Pöttgen C, Gauler TC,
Friedel G, Veit S, Heinrich V, Welter S, Budach W, Spengler W,
Kimmich M, et al: Phase III study of surgery versus definitive
concurrent chemoradiotherapy boost in patients with resectable
stage IIIA(N2) and selected IIIB non-small-cell lung cancer after
induction chemotherapy and concurrent chemoradiotherapy (ESPATUE).
J Clin Oncol. 33:4194–4201. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Provencio M, Nadal E, Insa A,
García-Campelo MR, Casal-Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, et al:
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell
lung cancer (NADIM): An open-label, multicentre, single-arm, phase
2 trial. Lancet Oncol. 21:1413–1422. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Provencio M, Serna-Blasco R, Nadal E, Insa
A, García-Campelo MR, Casal Rubio J, Dómine M, Majem M,
Rodríguez-Abreu D, Martínez-Martí A, et al: Overall survival and
biomarker analysis of neoadjuvant nivolumab plus chemotherapy in
operable stage IIIA non-small-cell lung cancer (NADIM phase II
trial). J Clin Oncol. 40:2924–2933. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Provencio M, Nadal E, González-Larriba JL,
Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo
V, Insa A, Ponce S, et al: Perioperative nivolumab and chemotherapy
in stage III non-small-cell lung cancer. N Engl J Med. 389:504–513.
2023.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dantoing E, Piton N, Salaün M, Thiberville
L and Guisier F: Anti-PD1/PD-L1 immunotherapy for non-small cell
lung cancer with actionable oncogenic driver mutations. Int J Mol
Sci. 22(6288)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Seegobin K, Majeed U, Wiest N, Manochakian
R, Lou Y and Zhao Y: Immunotherapy in non-small cell lung cancer
with actionable mutations other than EGFR. Front Oncol.
11(750657)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Grant MJ, Herbst RS and Goldberg SB:
Selecting the optimal immunotherapy regimen in driver-negative
metastatic NSCLC. Nat Rev Clin Oncol. 18:625–644. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yan N, Zhang H, Shen S, Guo S and Li X:
Response to immune checkpoint inhibitor combination therapy in
metastatic RET-mutated lung cancer from real-world retrospective
data. BMC Cancer. 24(178)2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bhandari NR, Hess LM, Han Y, Zhu YE and
Sireci AN: Efficacy of immune checkpoint inhibitor therapy in
patients with RET fusion-positive non-small-cell lung cancer.
Immunotherapy. 13:893–904. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Akers KG, Oskar S, Zhao B, Frederickson AM
and Arunachalam A: Clinical outcomes of PD-1/PD-L1 inhibitors among
patients with advanced or metastatic non-small cell lung cancer
with BRAF, ERBB2/HER2, MET, or RET alterations: A systematic
literature review. J Immunother. 47:128–138. 2024.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Burning Rock Dx. LungCore®
9-gene Panel Overview. Available online: https://www.brbiotech.com/service/c4 (Accessed on
2025-1-31).
|
|
14
|
Ettinger DS, Wood DE and Aisner DL: NCCN
guidelines version 2.2024 non-small cell lung cancer. National
Comprehensive Cancer Network, Plymouth Meeting, PA, 2024.
|
|
15
|
Chinese Society of Clinical Oncology
Guidelines Working Committee: Chinese Society of Clinical Oncology
(CSCO) guidelines for the diagnosis and treatment of non-small cell
lung cancer, 2024 edition. People's Medical Publishing House,
Beijing, p14, 2024.
|
|
16
|
Deng H, Liu J, Cai X, Chen J, Rocco G,
Petersen RH, Brunelli A, Ng CSH, D'Amico TA, Liang W and He J:
Radical minimally invasive surgery after immuno-chemotherapy in
initially-unresectable stage IIIB non-small cell lung cancer. Ann
Surg. 275:e600–e602. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zheng J, Li Y, Jin C, Ruan K, Sun K, Chen
H, Wang M, Zhang S and Zhou J and Zhou J: Efficacy and surgical
safety of sequential surgical resection after pembrolizumab plus
chemotherapy for initial unresectable stage IIIB non-small cell
lung cancer. Lung Cancer. 184(107326)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yue D, Wang W, Liu H, Chen Q, Chen C,
Zhang J, Bai F and Wang C: LBA58 Pathological response to
neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb)
chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts)
in the phase III (Ph3) RATIONALE-315 trial. Ann Oncol. 34 (Suppl
2)(S1299)2023.
|
|
19
|
Spigel DR, Faivre-Finn C, Gray JE, Vicente
D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R,
Quantin X, et al: Five-year survival outcomes from the PACIFIC
trial: Durvalumab after chemoradiotherapy in stage III
non-small-cell lung cancer. J Clin Oncol. 40:1301–1311.
2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jung HA, Noh JM, Sun JM, Lee SH, Ahn JS,
Ahn MJ, Pyo H, Ahn YC and Park K: Real world data of durvalumab
consolidation after chemoradiotherapy in stage III non-small-cell
lung cancer. Lung Cancer. 146:23–29. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mahul BA, Stephen BE, Frederick LG, Byrd
DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess
KR, Sullivan DC, et al: AJCC cancer staging manual, 8th edition.
Springer, New York, NY, p450, 2010.
|
|
22
|
Puri S, Saltos A, Perez B, Le X and Gray
JE: Locally advanced, unresectable non-small cell lung cancer. Curr
Oncol Rep. 22(31)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Heymach JV, Harpole D, Mitsudomi T, Taube
JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, et
al: Perioperative durvalumab for resectable non-small-cell lung
cancer. N Engl J Med. 389:1672–1684. 2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
He J, Gao S, Reck M, Harpole D, Mitsudomi
T, Taube JM, Lee KY, Horio Y, Runglodvatana Y, Aperghis M, et al:
OA12.06 Neoadjuvant durvalumab + chemotherapy followed by adjuvant
durvalumab in resectable EGFR-mutated NSCLC (AEGEAN). J Thorac
Oncol. 18 (11 Suppl):S72–S73. 2023.
|
|
25
|
Wakelee H, Liberman M, Kato T, Tsuboi M,
Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, et al:
Perioperative pembrolizumab for early-stage non-small-cell lung
cancer. N Engl J Med. 389:491–503. 2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang C, Sun YX, Yi DC, Jiang BY, Yan LX,
Liu ZD, Peng LS, Zhang WJ, Sun H, Chen ZY, et al: Neoadjuvant
sintilimab plus platinum-based chemotherapy in EGFR-mutant NSCLC:
An updated analysis of a phase 2 prospective trial
(NEOTIDE/CTONG2104). Cell Rep Med. 5(101615)2024.
|
|
27
|
Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H,
Wang J, Wang R, Ji C, Li S, et al: Osimertinib as neoadjuvant
therapy in patients with EGFR-mutant resectable stage II-IIIB lung
adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase
2b trial. Lung Cancer. 178:151–156. 2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ferrara R, Auger N, Auclin E and Besse B:
Clinical and translational implications of RET rearrangements in
non-small cell lung cancer. J Thorac Oncol. 13:27–45.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Adashek JJ, Desai AP, Andreev-Drakhlin AY,
Roszik J, Cote GJ and Subbiah V: Hallmarks of RET and co-occuring
genomic alterations in RET-aberrant cancers. Mol Cancer Ther.
20:1769–1776. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Osta BE and Ramalingam SS: RET fusion:
Joining the ranks of targetable molecular drivers in NSCLC. JTO
Clin Res Rep. 1(100050)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gainor JF, Curigliano G, Kim DW, Lee DH,
Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, et al:
Pralsetinib for RET fusion-positive non-small-cell lung cancer
(ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol.
22:959–969. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Drilon A, Oxnard GR, Tan DSW, Loong HHF,
Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, et
al: Efficacy of selpercatinib in RET fusion-positive non-small-cell
lung cancer. N Engl J Med. 383:813–824. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhou C, Solomon B, Loong HH, Park K, Pérol
M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, et al:
First-line selpercatinib or chemotherapy and pembrolizumab in RET
fusion-positive NSCLC. N Engl J Med. 389:1839–1850. 2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Marabelle A, Fakih M, Lopez J, Shah M,
Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin
JA, Miller WH Jr, et al: Association of tumour mutational burden
with outcomes in patients with advanced solid tumours treated with
pembrolizumab: Prospective biomarker analysis of the multicohort,
open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21:1353–1365.
2020.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lu C, Dong XR, Zhao J, Zhang XC, Chen HJ,
Zhou Q, Tu HY, Ai XH, Chen XF, An GL, et al: Association of genetic
and immuno-characteristics with clinical outcomes in patients with
RET-rearranged non-small cell lung cancer: A retrospective
multicenter study. J Hematol Oncol. 13(37)2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Offin M, Guo R, Wu SL, Sabari J, Land JD,
Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, et al:
Immunophenotype and response to immunotherapy of RET-rearranged
lung cancers. JCO Precis Oncol. 3(PO.18.00386)2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Nagahashi M, Sato S, Yuza K, Shimada Y,
Ichikawa H, Watanabe S, Takada K, Okamoto T, Okuda S, Lyle S, et
al: Common driver mutations and smoking history affect tumor
mutation burden in lung adenocarcinoma. J Surg Res. 230:181–185.
2018.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang X, Ricciuti B, Nguyen T, Li X, Rabin
MS, Awad MM, Lin X, Johnson BE and Christiani DC: Association
between smoking history and tumor mutation burden in advanced
non-small cell lung cancer. Cancer Res. 81:2566–2573.
2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Long JY, Li RZ, Wang DX, Liu H, Tian J,
Ding ZN, Yan LJ, Dong ZR, Hong JG, Tian BW, et al: Comprehensive
molecular analysis identifies RET alterations association with
response of ICIs in multi-immunotherapy cohorts. Int
Immunopharmacol. 126(111281)2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang Y, Wang Y, Li J, Li J and Che G:
Clinical significance of PIK3CA gene in non-small-cell lung cancer:
A systematic review and meta-analysis. Biomed Res Int.
2020(3608241)2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chen JY, Cheng YN, Han L, Wei F, Yu WW,
Zhang XW, Cao S and Yu JP: Predictive value of K-ras and PIK3CA in
non-small cell lung cancer patients treated with EGFR-TKIs: A
systemic review and meta-analysis. Cancer Biol Med. 12:126–139.
2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Saal LH, Holm K, Maurer M, Memeo L, Su T,
Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, et al:
PIK3CA mutations correlate with hormone receptors, node metastasis,
and ERBB2, and are mutually exclusive with PTEN loss in human
breast carcinoma. Cancer Res. 65:2554–2559. 2005.PubMed/NCBI View Article : Google Scholar
|
